Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atara Biotherapeutics

7.72
-0.2400-3.02%
Post-market: 7.950.2300+2.98%17:02 EDT
Volume:18.85K
Turnover:148.25K
Market Cap:52.46M
PE:-0.68
High:8.07
Open:7.93
Low:7.60
Close:7.96
Loading ...

Atara Biotherapeutics price target lowered to $17 from $21 at Canaccord

TIPRANKS
·
17 Jan

Atara Biotherapeutics Inc : Canaccord Genuity Cuts Target Price to $17 From $21

THOMSON REUTERS
·
17 Jan

Sector Update: Health Care Stocks Rise Thursday Afternoon

MT Newswires Live
·
17 Jan

Top Midday Decliners

MT Newswires Live
·
17 Jan

Atara Biotherapeutics Shares Plunge 38% Following FDA Response to EBVALLO Application

GuruFocus.com
·
17 Jan

Atara Biotherapeutics Shares Tumble Amid 'Compliance Issues' Involving Manufacturing Plant for Ebvallo

MT Newswires Live
·
17 Jan

US Stocks Edge Lower; Retail Sales Increase Less Than Expected

Benzinga
·
16 Jan

Atara Biotherapeutics Shares Down 43.8% After US FDA Declines to Approve Co's Cancer Therapy

THOMSON REUTERS
·
16 Jan

FDA Rejects Atara's Request to Bring Blood Cancer Treatment to Market

Dow Jones
·
16 Jan

BUZZ-Atara Biotherapeutics slumps after FDA declines to approve cancer therapy

Reuters
·
16 Jan

Atara Biotherapeutics Shares Resume Trading, Down 45% Premarket After US FDA Declines to Approve Co's Cancer Therapy

THOMSON REUTERS
·
16 Jan

BRIEF-Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLOTM (tabelecleucel)

Reuters
·
16 Jan

US FDA declines to approve Atara Biotherapeutics' cancer therapy

Reuters
·
16 Jan

Atara Biotherapeutics: Intends to Suspend All CAR-T Activities, Significantly Cut Expenses IF Resolution Not Reached for Funding for Programs in Q1

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Crl Did Not Identify Deficiencies Related to Clinical Efficacy or Safety Data in Bla

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Engaged Advisor to Support Exploration of All Strategic Options

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Provides Regulatory and Business Update on Ebvallotm (Tabelecleucel)

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics: Got Into Non-Binding Term Sheet With Redmile Group to Provide up to $15 Mln in Funding

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Inc: Received FDA Complete Response Letter (Crl) Solely Related to Inspection Findings at Third-Party Manufacturer

THOMSON REUTERS
·
16 Jan

Atara Biotherapeutics Shares Halted for News Pending Premarket

THOMSON REUTERS
·
16 Jan